Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05613894
What this trial is testing

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Utah 33
Large-scale testing (Phase 3)Ended earlyNCT01083615
What this trial is testing

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castrate-Resistant Prostate CancerHormone Refractory Prostate Cancer
Achieve Life Sciences 14
Not applicableStudy completedNCT04000776
What this trial is testing

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Université de Sherbrooke 100
Early research (Phase 1)UnknownNCT06237491
What this trial is testing

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
Yantai LNC Biotechnology Singapore PTE. LTD. 12
Early research (Phase 1)Ended earlyNCT05295927
What this trial is testing

EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 3
Testing effectiveness (Phase 2)Ended earlyNCT05177770
What this trial is testing

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer
Coherus Oncology, Inc. 16
Not applicableStudy completedNCT02432001
What this trial is testing

Radiologically Guided Biopsies of mCRPC

Who this might be right for
Prostate Cancer
University of California, San Francisco 256
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Not applicableActive Not RecruitingNCT06380738
What this trial is testing

Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 111
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Testing effectiveness (Phase 2)UnknownNCT05262608
What this trial is testing

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation

Who this might be right for
Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 30
Post-approval studies (Phase 4)Looking for participantsNCT06099093
What this trial is testing

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma
Brigham and Women's Hospital 30
Not applicableLooking for participantsNCT06141993
What this trial is testing

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

Who this might be right for
Prostate CancerProstate AdenocarcinomaProstate Cancer Metastatic+1 more
Duke University 120
Early research (Phase 1)Active Not RecruitingNCT06052306
What this trial is testing

Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Bayer 232
Not applicableNot Yet RecruitingNCT07697989
What this trial is testing

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

Who this might be right for
Prostatic Neoplasms, Castration-ResistantNeoplasm Metastasis
Novartis Pharmaceuticals 1,085
Testing effectiveness (Phase 2)Active Not RecruitingNCT05032040
What this trial is testing

XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Who this might be right for
Ovarian CancerClear Cell CarcinomaEndometrial Cancer+2 more
Xencor, Inc. 170
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Large-scale testing (Phase 3)Active Not RecruitingNCT05171816
What this trial is testing

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 110
Testing effectiveness (Phase 2)Ended earlyNCT04052204
What this trial is testing

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer 3
Large-scale testing (Phase 3)Ended earlyNCT04237584
What this trial is testing

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
MANA RBM 23
Next Page